Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects

Sufyan  Ibrahim; Smita  Shenoy; Ramya  Kateel; Shreya  Hegde; Amrita Parida; Lipsita  Samantaray

doi:10.5826/mrm.2024.992

Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects

Authors

Sufyan Ibrahim Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma Center, Oklahoma City, OK, USA.
Smita Shenoy Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India -576104.
Ramya Kateel Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India -576104.
Shreya Hegde Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India -576104
Amrita Parida Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India -576104.
Lipsita Samantaray Department of Medical Oncology, IMS & SUM Hospital, Bhubaneswar, India

DOI: https://doi.org/10.5826/mrm.2024.992

Keywords:

Non small cell cancer, thoracic cancer, malignancy

Abstract

There are many challenges that are faced in the treatment of Non-Small Cell Lung Cancer (NSCLC) due to the complexities associated with the tumor. Association of different types of mutations are one of the major complexities. Among these mutations, BRAF mutations are significantly gathering more attention due to their impact on disease progression and therapeutic response. This review provides an analysis of the current understanding of BRAF mutations in NSCLC, focusing on the molecular intricacies, clinical implications, and therapeutic advancements. The article explores the diverse spectrum of BRAF mutations, highlighting the prevalence of specific mutations such as V600E and non-V600E alterations. The review also highlights the intricate signalling pathways influenced by BRAF mutations, shedding light on their role in tumorigenesis and metastasis. Therapeutically, we critically evaluate the existing targeted therapies tailored for BRAF-mutant NSCLC, addressing their efficacy, limitations, and emerging resistance mechanisms. Furthermore, we outline ongoing clinical trials and promising investigational agents that hold potential for reshaping the treatment of NSCLC. This review provides comprehensive current information about the role of BRAF mutations in NSCLC. Understanding the molecular diversity, clinical implications, and therapeutic strategies associated with BRAF-mutant NSCLC is crucial for optimizing patient outcomes and steering the direction of future research in this evolving field.

References

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc 2008;83:584–94.

2. Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, et al. Current treatments for non-small cell lung cancer. Front Oncol 2022;12:945102.

3. Chen D, Zhang L-Q, Huang J-F, Liu K, Chuai Z-R, Yang Z, et al. BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Souglakos J, editor. PLoS ONE 2014;9:e101354.

4. Ardito F, Giuliani M, Perrone D, Troiano G, Muzio LL. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med 2017;40:271–80.

5. Ottaviano M, Giunta E, Tortora M, Curvietto M, Attademo L, Bosso D, et al. BRAF Gene and Melanoma: Back to the Future. IJMS 2021;22:3474.

6. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2007;1773:1263–84.

7. Gunderwala A, Cope N, Wang Z. Mechanism and inhibition of BRAF kinase. Curr Opin Chem Biol 2022;71:102205.

8. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 2018;37:3183–99.

9. Martinez Fiesco JA, Durrant DE, Morrison DK, Zhang P. Structural insights into the BRAF monomer-to--dimer transition mediated by RAS binding. Nat Commun 2022;13:486.

10. Hussain MRM, Baig M, Mohamoud HSA, Ulhaq Z, Hoessli DC, Khogeer GS, et al. BRAF gene: From human cancers to developmental syndromes. Saudi J of Biological Sciences 2015;22:359–73.

11. Poulikakos PI, Sullivan RJ, Yaeger R. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clin Cancer Res 2022;28:4618–28.

12. Shan KS, Rehman TU, Ivanov S, Domingo G, Raez LE. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers. IJMS 2024;25:624.

13. Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology 2022;85:123–54.

14. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, Von Kriegsheim A, et al. Raf Family Kinases: Old Dogs Have Learned New Tricks. Genes & Cancer 2011;2:232–60.

15. Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials. Genes & Diseases 2023;10:76–88.

16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54.

17. Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes 2020;11:1342.

18. Owsley J, Stein MK, Porter J, In GK, Salem M, O’Day S, et al. Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood) 2021;246:31–9.

19. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw 2018;16:807–21.

20. Dahui Q. Next-generation sequencing and its clinical application. Cancer Biol Med 2019;16:4–10.

21. Pesta M, Shetti D, Kulda V, Knizkova T, Houfkova K, Sharif Bagheri M, et al. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics 2022;12:1799.

22. Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update. South Asian J Cancer 2019;08:01–17.

23. Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Front Oncol 2022;12:863043.

24. Li H, Zhang Y, Xu Y, Huang Z, Cheng G, Xie M, et al. Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell Death Dis 2022;13:1064.

25. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, et al. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers (Basel) 2020;12:1823.

26. Anguera G, Majem M. BRAF inhibitors in metastatic non-small cell lung cancer. J Thorac Dis 2018;10:589–92.

27. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 2012;67:1265–72.

28. Gençler B, Gönül M. Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatol Res Pract 2016;2016:5361569.

29. Subbiah V, Baik C, Kirkwood JM. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer 2020;6:797–810.

30. Planchard D, Besse B, Kim TM, Quoix EA, Souquet PJ, Mazieres J, et al. Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. JCO 2017;35:9075–9075.

31. Riely GJ, Ahn M-J, Felip E, Ramalingam SS, Smit EF, Tsao AS, et al. Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncology 2022;18:781–91.

32. Long GV, Stroyakovsky DL, Gogas H, Levchenko E, De Braud F, Larkin JMG, et al. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. JCO 2014;32:9011–9011.

33. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma. Ann Onc 2014;25:v1.

34. Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, et al. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. Int J Mol Sci 2023;24:12840.

35. Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller--Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019;4:e000491.

36. Thoracic Cancer [Internet]. ASCO [cited 2024 Jan 18]. Available from: https://old-prod.asco.org/practice-patients/guidelines/thoracic-cancer

37. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up via stella. Ann Oncol 2023;34:339–57.

38. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:497–530.

39. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532–40.

40. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395:1835–44.

41. Lazar R, Fischbach C, Schott R, Somme L. Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review. Front Oncol 2024;14:1307882.

42. Tsamis I, Gomatou G, Chachali SP, Trontzas IP, Patriarcheas V, Panagiotou E, et al. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. Clin Transl Oncol 2022;25:10–20.

43. Abdayem P, Planchard D. Ongoing progress in BRAF-mutated non-small cell lung cancer. Clin Adv Hematol Oncol 2022;20:662–72.

44. Mezquita L, Oulhen M, Aberlenc A, Deloger M, Aldea M, Honore A, et al. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer. Br J Cancer [Internet] 2024 [cited 2024 Jan 31]; Available from: https://www.nature.com/articles/s41416-023-02535-0

45. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:642–50.

46. Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Onc 2020;31:289–94.

47. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1315–27.

48. Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Cancer Treat Rev 2018;66:82–94.

49. Chan XY, Singh A, Osman N, Piva TJ. Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int J Mol Sci 2017;18:1527.

50. Facchinetti F, Lacroix L, Mezquita L, Scoazec J-Y, Loriot Y, Tselikas L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer. Eur J Cancer 2020;132:211–23.

51. Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. J Thorac Oncol 2018;13:e131–3.

52. Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, et al. KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. J Thorac Oncol 2018;13:e249–51.

53. Tan L, Tran B, Tie J, Markman B, Ananda S, Tebbutt NC, et al. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. Clin Cancer Res 2023;29:1017–30.

54. Han R, Hao S, Lu C, Zhang C, Lin C, Li L, et al. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction. Mol Oncol 2020;14:1152–69.

55. Guaitoli G, Zullo L, Tiseo M, Dankner M, Rose AA, Facchinetti F. Non-small-cell lung cancer: how to manage BRAF-mutated disease. Drugs Context 2023;12:2022-11–3.

56. C4 Therapeutics, Inc. A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors [Internet]. clinicaltrials.gov; 2023 Nov. Report No.: NCT05668585. Available from: https://clinicaltrials.gov/study/NCT05668585

57. Black Diamond Therapeutics, Inc. A Phase 1, Open--label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms [Internet]. clinicaltrials.gov; 2024 Jan. Report No.: NCT05786924. Available from: https://clinicaltrials.gov/study/NCT05786924

58. Verastem, Inc. A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202) [Internet]. clinicaltrials.gov; 2024 Jan. Report No.: NCT04620330. Available from: https://clinicaltrials.gov/study/NCT04620330

59. Sullivan RJ, Weber J, Patel S, Dummer R, Carlino MS, Tan DSW, et al. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors. Clin Cancer Res. 2020;26:5102–12.

60. Shanghai Kechow Pharma, Inc. A Single-arm, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HL-085 Capsules Combined With Vemurafenib in the Treatment of BRAF V600E Mutated Patients With Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [Internet]. clinicaltrials.gov; 2023 Jun. Report No.: NCT05900219. Available from: https://clinicaltrials.gov/study/NCT05900219